Seeking Alpha

Seeking Alpha Portfolio App for iPad

607 people get VNDA articles and Market Currents by email alert.

Get email alerts on VNDA »

VNDA

Vanda Pharmaceuticals Inc.

6/19/2013, 3:43 AM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Tuesday, June 11, 3:21 PM Vanda Pharmaceuticals (VNDA +23.9%) soars after Baker Bros. more than doubles its position in the company from Q1. The hedge fund's stake now sits at 13.99%. A quick look at the options chain shows volume exceeded open interest at several strikes today for this months expiry. Comment! [Healthcare]
Tuesday, June 11, 12:45 PM Midday top 10 gainers: SGOC +56%. BEAT +53%. UQM +30%. PGNX +26%. DOLE +21%. NOA +21%. QCOR +20%. VNDA +19%. ALTI +13%. CMGE +13%.
Midday top 10 Losers: GNMK -23%. LULU -17%. SMA -16%. ALVR -15%. LDK -10%. PRIS -10%. RSOL -10%. IMUC -9%. ECTE -9%. COCO -9%. 1 Comment [On the Move]
Thursday, June 6, 8:03 AM Vanda Pharmaceuticals (VNDA) says that additional data from Phase III trials of the company's Tasimelteon treatment for Non-24-Hour Disorder "clearly demonstrate" that the medicine can train patients' master body clocks to the 24-hour day and that "continued treatment is necessary to maintain entrainment." Non-24-Hour Disorder affects most totally blind people. (PR) Comment! [Healthcare]
Wednesday, June 5, 9:15 AM Shares of Vanda Pharmaceuticals (VNDA) rise 2.36% premarket and look set to add to what has become quite a rally. The stock is up 109% over the past month, gathering momentum from analyst praise (I, II), positive commentary from the Tech Council of Maryland, and an NDA application for Tasimelteon. The company will present at the Jefferies Global Healthcare Conference tomorrow at 2:30. Comment! [Healthcare, On the Move]
Friday, May 31, 7:36 AM On the heels of yesterday's double-digit gains, Vanda Pharmaceuticals (VNDA) announces the submission of an NDA for Tasimelteon, which the company hopes can become the first FDA approved treatment for Non-24 hour disease in the totally blind. (PR) Comment! [Healthcare]
Friday, May 24, 12:45 PM Midday top 10 gainers: OTT +41%. ZIOP +25%. ESMC +18%. DRAM +17%. FCEL +17%. VNDA +17%. TNP +16%. BLDP +14%. BLOX +13%. VRTA +12%.
Midday top 10 Losers: DF -51%. RNIN -29%. ETAK -17%. SHLD -14%. HIHO -14%. HGSH -12%. PLM -11%. ANF -10%. TITN -10%. ARO -10%. 4 Comments [On the Move]
Friday, May 24, 12:32 PM Vanda Pharmaceuticals (VNDA +16.7%) pops today after the Tech Council of Maryland named the company Life Science Firm of the Year, outlining its encouraging research on tasimelteon, a circadian regulator for the treatment of Non-24-Hour Disorder. The disorder is a rare condition that affects blind people, for which there are currently no FDA-approved drugs. Comment! [Healthcare, On the Move]
Friday, May 17, 12:45 PM Midday top 10 gainers: RSOL +60%. VNDA +23%. SCTY +19%. ORMP +16%. VSAT +16%. COCO +16%. NBG +14%. MHGC +13%. JRCC +13%. MVIS +12%.
Midday top 10 losers: ARUN -27%. UNXL -23%. COSI -14%. AFOP -12%. MNGA -12%. FSGI -10%. YOKU -10%. ALIM -9%. EGLE -9%. GIG -9%. Comment! [On the Move]
Friday, May 17, 10:51 AM Vanda Pharmaceuticals (VNDA +20%) pops after Lazard pounds the table on the stock and ups its price target by nearly 55% to a whopping $17 from $11. The firm cites positive checks from sleep specialists on tasimelteon for non-24 hour insomnia disorder. Comment! [Healthcare, On the Move]
Friday, May 10, 1:49 PM Vanda Pharmaceuticals (VNDA +1%) moves up after Jefferies raises its price target from $6 to $7, saying that a Tasimelteon filing is forthcoming. The firm notes that VNDA has plenty of cash to make it through potential Tasi approval, and it continues to develop market awareness and build pre-launch demand critical mass. Comment! [Healthcare, On the Move]
Thursday, May 9, 7:09 AM Vanda Pharmaceuticals (VNDA): Q1 EPS of -$0.15 beats by $0.10. Revenue of $8.1M misses by $0.32M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, May 9, 12:05 AM Notable earnings before Thursday’s open: AES, AGU, ALR, AM, AMRC, APA, BAM, BCE, CBB, CNSL, CTB, CVC, DF, DISH, DNDN, GLP, GTIV, IRC, KEM, KIOR, MEA, NPSP, OWW, PCP, SNE, SNSS, SPH, SRPT, TK, TNK, VICL, VNDA, WAC, WFR, WIN, WWAV, XRAY Comment! [Earnings]
Wednesday, May 8, 5:30 PM Notable earnings before Thursday’s open: AES, AGU, ALR, AM, AMRC, APA, BAM, BCE, CBB, CNSL, CTB, CVC, DF, DISH, DNDN, GLP, GTIV, IRC, KEM, KIOR, MEA, NPSP, OWW, PCP, SNE, SNSS, SPH, SRPT, TK, TNK, VICL, VNDA, WAC, WFR, WIN, WWAV, XRAY Comment! [Earnings]
Thursday, February 14, 1:46 PM Vanda Pharmaceuticals (VNDA +2.4%) moves up after Jefferies raised its rating to Buy on the shares earlier today, and ups its price target from $3.50 to $6.00. The firm cites surprisingly good Phase 3 data for Tasimelteon, noting that even the drugs conservatively discounted contribution is likely to have a big upside from current negative EV level. Comment! [Healthcare, On the Move]
Tuesday, February 12, 12:05 AM Notable earnings before Tuesday’s open: AB, AVP, DBD, FIS, FOSL, GT, HCP, HERO, HUN, KO, KORS, LVLT, MHP, MMC, OHI, OMC, RAI, SPR, TGH, TRP, UTHR, VAL, VNDA Comment! [Earnings]
Monday, February 11, 5:30 PM Notable earnings before Tuesday’s open: AB, AVP, DBD, FIS, FOSL, GT, HCP, HERO, HUN, KO, KORS, LVLT, MHP, MMC, OHI, OMC, RAI, SPR, TGH, TRP, UTHR, VAL, VNDA Comment! [Earnings]